EQT is nearing a deal to acquire Qiagen for around €9.6 billion, bringing an end to years of takeover speculation involving the European molecular testing company
EQT AGREES TO TAKE QIAGEN PRIVATE AT €46.50 PER SHARE
Qiagen signed a business combination agreement with EQT Private Equity, whose offer needs acceptance from at least 50% plus one share. Qiagen's Frankfurt and NYSE listings will end after closing, and the company suspended its full-year 2026 outlook, per Qiagen
EQT NEARS A $10.8 BILLION DEAL TO BUY QIAGEN
EQT is nearing a deal to acquire the European molecular testing company for about €9.6 billion, ending years of takeover speculation, according to people familiar with the matter, per Bloomberg